Cancer Letters
Volume 290, Issue 2 , Pages 139-147 , 28 April 2010

An epitome of DNA repair related genes and mechanisms in thyroid carcinoma

  • Elisavet Gatzidou

      Affiliations

    • Department of Forensic Medicine and Toxicology, National and Kapodistrian University of Athens, Medical School, Athens, Greece
    • ,
  • Christina Michailidi

      Affiliations

    • Department of Forensic Medicine and Toxicology, National and Kapodistrian University of Athens, Medical School, Athens, Greece
    • ,
  • Sophia Tseleni-Balafouta

      Affiliations

    • Department of Pathology, National and Kapodistrian University of Athens, Medical School, Athens, Greece
    • ,
  • Stamatios Theocharis

      Affiliations

    • Department of Forensic Medicine and Toxicology, National and Kapodistrian University of Athens, Medical School, Athens, Greece
    • Corresponding Author InformationCorresponding author.

Received 10 May 2009 ,Revised 31 July 2009 ,Accepted 2 August 2009.

References 

  1. Leenhardt L, Grosclaude P, Cherie-Challine L. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid. 2004;14:1056–1060
  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J. Clin. 2008;58:71–96
  3. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–2167
  4. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995. Cancer. 1998;83:2638–2648
  5. Sturgis EM, Zhao C, Zheng R, Wei Q. Radiation response genotype and risk of differentiated thyroid cancer: a case-control analysis. Laryngoscope. 2005;115:938–945
  6. Little JB. Radiation carcinogenesis. Carcinogenesis. 2000;21:397–404
  7. Friedberg EC, McDaniel LD, Schultz RA. The role of endogenous and exogenous DNA damage and mutagenesis. Curr. Opin. Genet. Dev. 2004;14:5–10
  8. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411:366–374
  9. Pecorino L. Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics. first ed.. New York: Oxford University Press; 2005;
  10. Giaginis C, Gatzidou E, Theocharis S. DNA repair systems as targets of cadmium toxicity. Toxicol. Appl. Pharmacol. 2006;213:282–290
  11. Lindahl T. Suppression of spontaneous mutagenesis in human cells by DNA base excision-repair. Mutat. Res. 2000;462:129–135
  12. Nilsen H, Krokan HE. Base excision repair in a network of defence and tolerance. Carcinogenesis. 2001;22:987–998
  13. Krokan HE, Nilsen H, Skorpen F, Otterlei M, Slupphaug G. Base excision repair of DNA in mammalian cells. FEBS Lett. 2000;476:73–77
  14. Memisoglu A, Samson L. Base excision repair in yeast and mammals. Mutat. Res. 2000;451:39–51
  15. Frosina G, Fortini P, Rossi O, Carrozzino F, Raspaglio G, Cox LS, et al. Two pathways for base excision repair pathways in mammalian cells. J. Biol. Chem. 1996;271:9573–9578
  16. Friedberg EC. How nucleotide excision repair protects against cancer. Nat. Rev. Cancer. 2001;1:22–33
  17. Peterson CL, Côté J. Cellular machineries for chromosomal DNA repair. Genes Dev. 2004;18:602–616
  18. Pâques F, Haber JE. Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 1999;63:349–404
  19. Jackson SP. Sensing and repairing DNA double-strand breaks. Carcinogenesis. 2002;23:687–696
  20. Thompson LH, Schild D. Recombinational DNA repair and human disease. Mutat. Res. 2002;509:49–78
  21. Collis SJ, DeWeese TL, Jeggo PA, Parker AR. The life and death of DNA–PK. Oncogene. 2005;24:949–961
  22. Evans E, Alani E. Roles for mismatch repair factors in regulating genetic recombination. Mol. Cell Biol. 2000;20:7839–7844
  23. Kolodner RD, Marsischky GT. Eukaryotic DNA mismatch repair. Curr. Opin. Genet. Dev. 1999;9:89–96
  24. Ray BL, White CI, Haber JE. Heteroduplex formation and mismatch repair of the “stuck” mutation during mating-type switching in Saccharomyces cerevisiae. Mol. Cell Biol. 1991;11:3380–5372
  25. Buermeyer AB, Deschênes SM, Baker SM, Liskay RM. Mammalian DNA mismatch repair. Annu. Rev. Genet. 1999;33:533–564
  26. Marti TM, Kunz C, Fleck O. DNA mismatch repair and mutation avoidance pathways. J. Cell. Physiol. 2002;191:28–41
  27. Harfe BD, Jinks-Robertson S. DNA mismatch repair and genetic instability. Annu. Rev. Genet. 2000;34:359–399
  28. Hsieh P. Molecular mechanisms of DNA mismatch repair. Mutat. Res. 2001;486:71–87
  29. Acharya S, Wilson T, Gradia S, Kane MF, Guerrette S, Marsischky GT, et al. hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc. Natl. Acad. Sci. USA. 1996;93:13629–13634
  30. McCulloch SD, Gu L, Li GM. Bi-directional processing of DNA loops by mismatch repair-dependent and-independent pathways in human cells. J. Biol. Chem. 2003;278:3891–3896
  31. Wilson T, Guerrette S, Fishel R. Dissociation of mismatch recognition and ATPase activity by hMSH2–hMSH3. J. Biol. Chem. 1999;274:21659–21664
  32. Ban C, Junop M, Yang W. Transformation of MutL by ATP binding and hydrolysis: a switch in DNA mismatch repair. Cell. 1999;97:85–97
  33. Caldecott KW, Tucker JD, Stanker LH, Thompson LH. Characterization of XRCC1–DNA ligase III complex in vitro and its absence from mutant hamster cells. Nucleic Acids Res. 1995;23:4836–4843
  34. Thompson LH, West MG. XRCC1 keeps DNA from getting stranded. Mutat. Res. 2000;459:1–18
  35. Ho T, Li G, Lu J, Zhao C, Wei Q, Sturgis EM. Association of XRCC1 polymorphisms and risk of differentiated thyroid carcinoma: a case-control analysis. Thyroid. 2009;19:129–135
  36. Chiang FY, Wu CW, Hsiao PJ, Kuo WR, Lee KW, Lin JC, et al. Association between polymorphisms in DNA base excision repair genes XRCC1, APE1, and ADPRT and differentiated thyroid carcinoma. Clin. Cancer Res. 2008;14:5919–5924
  37. Mertens AC, Mitby PA, Radloff G, Jones IM, Perentesis J, Kiffmeyer WR, et al. XRCC1 and glutathionine-S-transferase gene polymorphisms and susceptibility to radiotherapy-related malignancies in survivors of Hodgkin disease: a report from the Childhood Cancer Survivor study. Cancer. 2004;101:1463–1472
  38. Evans AR, Limp-Foster M, Kelley MR. Going APE over ref-1. Mutat. Res. 2000;461:83–108
  39. Chiarini LB, Freitas FG, Petrs-Silva H, Linden R. Evidence that the bifunctional redox factor/AP endonuclease Ref-1 is an anti-apoptotic protein associated with differentiation in the developing retina. Cell Death Differ. 2000;7:272–281
  40. Russo D, Celano M, Bulotta S, Bruno R, Arturi F, Giannasio P, et al. APE/Ref-1 is increased in nuclear fractions of human thyroid hyperfunctioning nodules. Mol. Cell. Endocrinol. 2002;194:71–76
  41. Tell G, Crivellato E, Pines A, Paron I, Pucillo C, Manzini G, et al. Mitochondrial localization of APE/Ref-1 in thyroid cells. Mutat. Res. 2001;485:143–152
  42. Ronen A, Glickman BW. Human DNA repair genes. Environ. Mol. Mutagen. 2001;37:241–283
  43. Lehmann AR. The xenoderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. Genes Dev. 2001;15:15–23
  44. Silva SN, Gil OM, Oliveira VC, Cabral MN, Azevedo AP, Faber A, et al. Association of polymorphisms in ERCC2 gene with non-familial thyroid cancer risk. Cancer Epidemiol. Biomarkers Prev. 2005;14:2407–2412
  45. Guan H, Ji M, Hou P, Liu Z, Wang C, Shan Z, et al. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T 1799A BRAF mutation in patients with papillary thyroid cancer. Cancer. 2008;113:247–255
  46. Ruschenburg I, Vollheim B, Stachura J, Cordon-Cardo C, Korabiowska M. Analysis of DNA mismatch repair gene expression and mutations in thyroid tumours. Anticancer Res. 2006;26:2107–2112
  47. Schofield MJ, Hsieh P. DNA mismatch repair: molecular mechanisms and biological function. Annu. Rev. Microbiol. 2003;57:579–608
  48. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363:558–561
  49. Weber JL, May PE. Abundant class of DNA polymorphism which can be typed using the polymerase chain reaction. Am. J. Hum. Genet. 1989;44:388–396
  50. Wheeler JM, Bodmer WF, Mortensen NJ. DNA mismatch repair genes and colorectal cancer. Gut. 2000;47:148–153
  51. Parsons R, Li GM, Longley MJ, Fang WH, Papadopoulos N, Jen J, et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell. 1993;75:1227–1236
  52. Shibata D, Peinado MA, Ionov Y, Malkhosyan S, Perucho M. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat. Genet. 1994;6:273–281
  53. Farid NR, Shi Y, Zou M. Molecular basis of thyroid cancer. Endocr. Rev. 1994;15:202–232
  54. Frayling IM. Microsatellite instability. Gut. 1999;45:1–4
  55. Vermiglio F, Schlumberger M, Lazar V, Lefreré I, Bressac B. Absence of microsatellite instability in thyroid carcinomas. Eur. J. Cancer. 1995;31A:128
  56. Soares P, dos Santos NR, Seruca R, Lothe RA, Sobrinho-Simões M. Benign and malignant thyroid lesions show instability at microsatellite loci. Eur. J. Cancer. 1997;33:293–296
  57. Vaish M, Mishra SK, Mandhani A, Mittal RD, Mittal B. Assessment of microsatellite instability in bladder and thyroid malignancies. Teratog. Carcinog. Mutagen. 2003;(Suppl. 1):255–265
  58. Vaish M, Mishra A, Kaushal M, Mishra SK, Mittal B. Microsatellite instability and its correlation with clinicopathological features in a series of thyroid tumors prevalent in iodine deficient areas. Exp. Mol. Med. 2004;36:122–129
  59. Tebbs RS, Zhao Y, Tucker JD, Scheerer JB, Siciliano MJ, Hwang M, et al. Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene. Proc. Natl. Acad. Sci. USA. 1995;92:6354–6358
  60. Liu N, Lamerdin JE, Tebbs RS, Schild D, Tucker JD, Shen MR, et al. XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. Mol. Cell. 1998;1:783–793
  61. Masson JY, Stasiak AZ, Stasiak A, Benson FE, West SC. Complex formation by the human RAD51C and XRCC3 recombination repair proteins. Proc. Natl. Acad. Sci. USA. 2001;98:8440–8446
  62. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 1998;58:604–608
  63. Fleck O, Nielsen O. DNA repair. J. Cell Sci. 2004;117:515–517
  64. Siraj AK, Al-Rasheed M, Ibrahim M, Siddqui K, Al-Dayel F, Al-Sanea O, et al. RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population. J. Endocrinol. Invest. 2008;31:893–899
  65. Bell S, Klein C, Müller L, Hansen S, Buchner J. p53 contains large unstructured regions in its native state. J. Mol. Biol. 2002;322:917–927
  66. Farid NR. p53 mutations in thyroid carcinoma: tidings from an old foe. J. Endocrinol. Invest. 2001;24:536–545
  67. McCabe CJ, Gittoes NJ. PTTG – a new pituitary tumour transforming gene. J. Endocrinol. 1999;162:163–166
  68. Tfelt-Hansen J, Kanuparthi D, Chattopadhyay N. The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin. Med. Res. 2006;4:130–137
  69. Heaney AP, Nelson V, Fernando M, Horwitz G. Transforming events in thyroid tumorigenesis and their association with follicular lesions. J. Clin. Endocrinol. Metab. 2001;86:5025–5032
  70. Boelaert K, McCabe CJ, Tannahill LA, Gittoes NJ, Holder RL, Watkinson JC, et al. Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 2003;88:2341–2347
  71. Kim D, Pemberton H, Stratford AL, Buelaert K, Watkinson JC, Lopes V, et al. Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene. 2005;24:4861–4866
  72. Kim DS, Franklyn JA, Boelaert K, Eggo MC, Watkinson JC, McCabe CJ. Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway. J. Clin Endocrinol. Metab. 2006;91:4603–4611
  73. Stratford AL, Boelaert K, Tannahill LA, Kim DS, Warfield A, Eggo MC, et al. Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis. J. Clin. Endocrinol. Metab. 2005;90:4341–4349
  74. Sáez C, Martínez-Brocca MA, Castilla C, Soto A, Navarro E, Tortolero M, et al. Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 2006;91:1404–1409
  75. Salehi F, Kovacs K, Scheithauer BW, Lloyd RV, Cusimano M. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocr. Relat. Cancer. 2008;15:721–743
  76. Romero F, Multon MC, Ramos-Morales F, Domínguez A, Bernal JA, Pintor-Toro JA, et al. Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res. 2001;29:1300–1307
  77. Kim CS, Ying H, Willingham MC, Cheng SY. The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer. Carcinogenesis. 2007;28:932–939
  78. Rubinek T, Chesnokova V, Wolf I, Wawrowsky K, Vlotides G, Melmed S. Discordant proliferation and differentiation in pituitary tumor-transforming gene-null bone marrow stem cells. Am. J. Physiol. Cell Physiol. 2007;293:C1082–C1092
  79. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, Kovacs K, et al. Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res. 2007;67:10564–10572
  80. Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene. 1994;9:509–516
  81. Minoletti F, Butti MG, Coronelli S, Miozzo M, Sozzi G, Pilotti S, et al. The two genes generating RET/PTC3 are localized in chromosomal band 10q11.2. Genes Chromosomes Cancer. 1994;11:51–57
  82. Nikiforov YE, Koshoffer A, Nikiforova M, Stringer J, Fagin JA. Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas. Oncogene. 1999;18:6330–6334
  83. Bongarzone I, Butti MG, Fugazzola L, Pacini F, Pinchera A, Vorontsova TV, et al. Comparison of the breakpoint regions of ELE1 and RET genes involved in the generation of RET/PTC3 oncogene in sporadic and in radiation-associated papillary thyroid carcinomas. Genomics. 1997;42:252–259
  84. Klugbauer S, Pfeiffer P, Gassenhuber H, Beimfohr C, Rabes HM. RET rearrangements in radiation-induced papillary thyroid carcinomas: high prevalence of topoisomerase I sites at breakpoints and microhomology-mediated end joining in ELE1 and RET chimeric genes. Genomics. 2001;73:149–160
  85. Povirk LF. Biochemical mechanisms of chromosomal translocations resulting from DNA double-strand breaks. DNA Repair. 2006;5:1199–1212
  86. Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene. 1995;11:2459–2467
  87. Fugazzola L, Pilotti S, Pinchera A, Vorontsova TV, Mondellini P, Bongarzone I, et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res. 1995;55:5617–5620
  88. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997;57:1690–1694
  89. Smida J, Salassidis K, Hieber L, Zitzelsberger H, Kellerer AM, Demidchik EP, et al. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. Int. J. Cancer. 1999;80:32–38
  90. Rabes HM, Klugbauer S. Molecular genetics of childhood papillary thyroid carcinomas after irradiation: high prevalence of RET rearrangement. Recent Results Cancer Res. 1998;154:248–264
  91. Pierotti MA, Santoro M, Jenkins RB, Sozzi G, Bongarzone I, Grieco M, et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc. Natl. Acad. Sci. USA. 1992;89:1616–1620
  92. Rabes HM. Gene rearrangements in radiation-induced thyroid carcinogenesis. Med. Pediatr. Oncol. 2001;36:574–582
  93. Sozzi G, Bongarzone I, Miozzo M, Borrello MG, Butti MG, Pilotti S, et al. A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma. Gene Chromosomes Cancer. 1994;9:244–250
  94. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr. Pathol. 2002;13:3–16
  95. Elisei R, Cosci B, Romei C, Agate L, Piampiani P, Miccoli P, et al. Identification of a novel point mutation in the RET gene (Ala833Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. J. Clin. Endocrinol. Metab. 2004;89:5823–5827

PII: S0304-3835(09)00523-0

doi: 10.1016/j.canlet.2009.08.007

Cancer Letters
Volume 290, Issue 2 , Pages 139-147 , 28 April 2010

Article Tools

* Image Usage & Resolution